Introduction {#sec1}
============

Lung cancer has increased in incidence over the past several decades, and is a major health problem throughout the world.[@bib1], [@bib2] In Japan, owing to a similar increasing trend,[@bib3] lung cancer is currently the second and fourth most common type of cancer in males and females, respectively.[@bib4] Smoking is a well-known strong risk factor for the development of lung cancer.[@bib5] However, the frequency of this unfavorable habit is still higher in Japanese males compared with males in the Western countries.[@bib6] Thus, the prevalence of lung cancer may have a possibility to remain high in Japanese males. Meanwhile, different cause-effect relationships exist between smoking and the onset of lung cancer when taking histological type into consideration; smoking has a greater effect on the incidence of squamous cell carcinoma and small cell carcinoma, as compared to other histological types.[@bib5]

Lung cancer is a fatal malignancy.[@bib1], [@bib2] The latest Japanese National Vital Statistics reported a total of 73,396 annual deaths due to cancer of the lung, trachea and bronchus (52,505 deaths in males and 20,891 deaths in females).[@bib7] As a result, lung cancer is the leading cause of cancer-related death in Japanese males and the second leading cause of cancer-related death in Japanese females, respectively.[@bib7] This poor prognosis is mainly due to the unfavorable fact that lung cancer is often diagnosed at an advanced stage.[@bib8], [@bib9], [@bib10], [@bib11] The frequency of late diagnosis of lung cancer also varies among histological types.[@bib10], [@bib11]

The BioBank Japan (BBJ) Project is a large patient-based biobank designed to implement personalized medicine for common diseases such as cancer and cardiovascular disease. Since the morbidity and mortality of lung cancer are different between males and females,[@bib4], [@bib7] it is worthwhile to examine clinical characteristics and mortality of lung cancer patients by sex. In this study, we attempted to investigate lifestyle and clinical characteristics of Japanese lung cancer patients and their prognosis by sex, using the BBJ Project database.

Participants and methods {#sec2}
========================

Study design and population {#sec2.1}
---------------------------

Details of the study design and protocol of the BBJ Project were described elsewhere.[@bib12], [@bib13] Briefly, the project enrolled patients with any of 47 common target diseases including lung cancer between June 2003 and March 2008, from 66 hospitals consisting of 12 cooperating medical institutions throughout Japan. This project collected clinical information and biological samples from participants annually until March 2013, regardless of whether the patients were newly diagnosed or treated cases. This project also followed up participants who had at least one of 32 diseases until 2014. The study protocol of the BBJ Project was approved by the research ethics committees of the Institute of Medical Science, the University of Tokyo, RIKEN Yokohama Institute and the 12 cooperating medical institutions. Written informed consent was obtained from all participants.

The BBJ Project originally enrolled 3779 lung cancer patients (2428 males and 1351 females). Of the 3779 participants, 197 were excluded due to missing data on the time from their diagnosis of lung cancer to study entry. Accordingly, we described the overview of lifestyle factors and clinical profiles of the remaining 3582 lung cancer patients (2299 males and 1283 females). To describe the characteristics of possible newly diagnosed lung cancer patients, we selected 1179 participants (764 males and 415 females) who were registered in the BBJ Project within 90 days after their diagnosis of lung cancer. Of these 1179 participants, 59 were excluded due to refusal to participate in the follow-up survey (n = 57) or loss of follow-up (n = 2). Thus, 1120 participants (728 male and 392 female) were included in the survival analyses to examine the prognosis and its risk factors in lung cancer patients.

Data collection {#sec2.2}
---------------

Clinical data were collected at study entry via interviews and medical records.[@bib14] The data included age at study entry, time from the diagnosis of lung cancer to study entry, height, weight, smoking habits, alcohol intake, past history, family history and clinical information at study entry including laboratory examination data (e.g., blood chemical markers and imaging data). Body mass index was calculated as weight in kilograms divided by height in meters squared. The blood chemical marker used in this report was serum carcinoembryonic antigen (CEA) level. The stage of lung cancer was classified according to the Japanese Classification of Lung Cancer, the 6th edition (2003). In this report, stage was primarily determined by the findings of pathologic stage, while missing data of pathologic stage were complemented with the findings of clinical stage. The histological type of lung cancer was determined primarily based on the findings in surgically resected tissues, while missing histological data were complemented with the findings from biopsy or cytological samples.

Follow-up survey {#sec2.3}
----------------

Follow-up survival survey was conducted until 2014 to determine whether the status of each participant was alive, relocated, unidentified, or dead by confirming their residence cards.[@bib15] The new addresses of participants who relocated were also recorded in the next survival survey. The date of death was also recorded for deceased participants. The outcome assessed in this study was death due to all causes. Details of the follow-up survey were described elsewhere.[@bib13], [@bib15]

Statistical analysis {#sec2.4}
--------------------

We performed a descriptive analysis of lifestyle and clinical characteristics of lung cancer patients for males and females separately, because smoking habits influences the proportion of histological type and cancer stage at diagnosis of lung cancer.[@bib5], [@bib10], [@bib11] The characteristics of interest were age at study entry, body mass index, smoking and drinking habits, comorbidities of chronic obstructive pulmonary disease and interstitial pneumonia/pulmonary fibrosis, family history of lung cancer, stage, histological type, and serum CEA level. The frequency of each characteristic was calculated in male and female study participants after excluding those with missing data. This analysis was performed in all participants and participants who were registered in the BBJ Project within 90 days after their diagnosis of lung cancer. The same analysis was conducted after stratifying the participants by age at study entry (20--59 versus ≥60 years old) or histological type.

We evaluated the prognosis of lung cancer in participants registered within 90 days after their diagnosis for male and female separately and for males and females combined. We calculated the 5-year relative survival rate by dividing the 5-year cumulative survival rate by the sex- and age-adjusted expected survival rate in our eligible lung cancer patients. The 5-year cumulative survival rate was calculated, using the Kaplan--Meier method. The expected survival rate was calculated, using a survival-rate table of a reference Japanese cohort from the Cancer Registry and Statistics, Cancer Information Service, National Cancer Center, Japan,[@bib16] which was based on sex- and age-specific mortality rates and Gompertz-Makeham\'s law in abridged life tables, published annually by the Statistics and Information Department of the Ministry of Health, Labour and Welfare, Japan.[@bib17]

We examined the impact of lifestyle and clinical characteristics on all-cause mortality in lung cancer patients registered within 90 days after their diagnosis, with males and females combined. We used a Cox proportional hazards model to estimate the hazard ratios and 95% confidence intervals (CIs) for mortality for each characteristic category, with one category set as the reference. The model was stratified by sex and institution to account for variability in baseline hazards between sexes and among the institutions. The model incorporated age at study entry (years as a continuous variable) and the entry year (2003, 2004, 2005, 2006, 2007 and 2008, setting year 2003 as the reference) in addition to each characteristic. We examined the association between BMI and mortality using a continuous variable, as well as the categorical variable. In this analyses, we excluded the participants with missing data or the group of small number of participants. Similar analyses were conducted only for participants with adenocarcinoma, the most common histological type of lung cancer.[@bib8], [@bib9], [@bib10], [@bib11]

All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). All p values were two-tailed, and the significance level was set at p \< 0.05.

Results {#sec3}
=======

Characteristics of all participants with lung cancer {#sec3.1}
----------------------------------------------------

Among 2299 male and 1283 female lung cancer patients aged ≥20 years at the enrollment, the mean (standard deviation) age at study entry was 67.5 (9.6) years for males and 65.9 (9.8) years for females. The distribution of the participants according to age at study entry is illustrated in [Fig. 1](#fig1){ref-type="fig"}; age distribution was slightly negatively skewed in both sexes, with the peak in the 70--74 year age group for males and the 65--69 year age group for females. The distribution of all the male and female participants, according to the time from the diagnosis to study entry was as follows: 33.2% and 32.3% for ≤90 days, 24.0% and 19.9% for 91--365 days, 29.6% and 33.0% for 1--4 years, 10.2% and 11.2% for 5--9 years, 2.3% and 2.8% for 10--14 years, 0.5% and 0.7% for 15--19 years, 0.2% and 0.1% for ≥20 years. [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"} summarize other characteristics of the male and female lung cancer patients, respectively. Male and female participants who had a history of smoking at study entry (current or former smoker) accounted for nearly 90% and 30% of known cases, respectively. Over 10% of male and female participants had a family history of lung cancer. Among the participants with stage information, over half of males and approximately two-thirds of females were classified as stage I at study entry, while nearly one-tenth were diagnosed as stage IV. In both sexes, adenocarcinoma was the most common histological type followed by squamous cell carcinoma, small cell carcinoma, and large cell carcinoma, although the proportion of adenocarcinoma was higher in females compared with males. Over one-fourth of males and one-fifth of females had a serum CEA of 5 ng/mL or higher, respectively.

Characteristics of participants registered within 90 days year after diagnosis {#sec3.2}
------------------------------------------------------------------------------

Of all lung cancer patients aged ≥20 years, 764 male and 415 female participants were registered within 90 days after the diagnosis of lung cancer. The mean age (standard deviation) at study entry was 66.0 (9.6) years for males and 64.7 (9.4) years for females. Age distribution of these participants were shifted to younger as younger as compared to the overall participants for both sexes ([Fig. 1](#fig1){ref-type="fig"}). In both sexes, the frequency of stage IV was slightly higher and the proportion of serum CEA ≥5 ng/mL was higher in those registered within 90 days compared with the overall participants ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}). In females, the frequency of ever smoker was higher in those registered within 90 days compared with the overall participants ([Table 2](#tbl2){ref-type="table"}). Other characteristics were similar for those registered within 90 days and the overall participants in both sexes.

When these male and female participants were stratified by age at study entry, there were several differences between the younger (aged 59 years or less) and older (aged 60 years or more) groups ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}). In males, adenocarcinoma was more predominant in the younger group compared with the older group, although adenocarcinoma was the most common histological type in both age groups. In females, the frequencies of ever smoker, alcohol drinker and a positive family history of lung cancer was higher in the younger group than in the older group, while the frequencies of obesity was lower in the younger, than older, age group. In both sexes, the frequency of participants with serum CEA ≥5 ng/mL was higher in the older group than in the younger group.

When these participants were stratified by histological type, we found the differences in several characteristics ([Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"}). The frequency of ever smoker was predominant in all histological types except for adenocarcinoma in females. In males, small cell carcinoma was detected at more advanced stages compared with the other types, while in females, squamous cell carcinoma and small cell carcinoma was detected at more advanced stages compared with the remaining two types. In both sexes, adenocarcinoma and large cell carcinoma were distributed at younger age levels, as compared to squamous cell carcinoma or small cell carcinoma. Furthermore, participants with small cell carcinoma had the highest frequency of serum CEA ≥5 ng/mL among all histological types.

Prognosis of participants registered within 90 days year after diagnosis {#sec3.3}
------------------------------------------------------------------------

Among the 1120 participants involved in the survival survey, the mean (standard deviation) follow-up period was 5.2 (3.4) years in a total of 5811 person-years of follow-up. During the follow-up period, 572 deaths were identified in the total period and 471 were identified during the 5 years of follow-up. Consequently, the 5-year cumulative survival rate was 57.1% (95% CI, 54.2--60.0%). The 5-year relative survival rate was 62.8% (95% CI, 59.5--66.0%). In males, the 5-year cumulative survival rate was 49.2% (95% CI, 45.5--52.9%), while the 5-year relative survival rate was 55.4% (95% CI, 51.3--59.6%). In females, the 5-year cumulative survival rate was 71.9% (95% CI, 67.4--76.4%), while the 5-year relative survival rate was 75.6% (95% CI, 70.9--80.4%).

[Table 5](#tbl5){ref-type="table"} shows which clinical characteristics will affect all-cause mortality in male and female-combined participants. The risk of all-cause mortality increased with increasing age at study. In addition, low body mass index, and ever smoker, more advanced stage, squamous cell or small cell carcinoma, and elevated serum CEA level were crudely associated with an increased risk of all-cause mortality after adjustment for age at study entry and entry year ([Table 5](#tbl5){ref-type="table"}).

When we focused on the participants with adenocarcinoma, similar relationships between clinical characteristics and all-cause mortality were observed ([Table 5](#tbl5){ref-type="table"}).

Discussion {#sec4}
==========

In this report, we described the lifestyle and clinical characteristics of Japanese male and female lung cancer patients involved in the BBJ Project. As compared to the results of lung cancer patients in the Patient Survey in Japan, 2005 ([Fig. 1](#fig1){ref-type="fig"}),[@bib18] our registry contained a greater proportion of younger age distribution in both sexes. In both sexes, stage and serum CEA level were worse in those registered within 90 days compared with the overall participants. As anticipated from the evidence that smoking is a strong risk factor for lung cancer,[@bib5] our study population had a much higher frequency of ever smoker than a general Japanese population for both sexes.[@bib19]

A report of the Japanese Lung Cancer (JLC) Registry showed that the frequency of each stage was 0.3% for stage 0, 29.3% for stage IA, 15.5% for stage IB, 1.4% for stage IIA, 6.3% for stage IIB, 11.7% for stage IIIA, 14.5% for stage IIIB, and 20.9% for stage IV in newly diagnosed lung cancer patients registered in 2002 throughout Japan.[@bib10] Another Japanese registry, which was comprised of patients at two major hospitals in Tokushima prefecture between 1999 and 2009, reported that the frequency was 22% for stage IA, 10% for stage IB, 1% for stage IIA, 5% for stage IIB, 11% for stage IIIA, 17% for stage IIIB, and 31% for stage IV.[@bib11] Our participants, even those registered within 90 days after diagnosis, had less advanced stages of lung cancer, compared with these two registries. One possible explanation may be the difference in the definition of cancer stages. Stage used in this report was determined using either pathologic stage or clinical stage, whereas two registries used clinical stages. Another explanation for this difference may be the differences in participating hospitals among the registries.

The JLC Registry reported that the proportion of histological types of lung cancer was 57.5% for adenocarcinoma, 26.1% for squamous cell carcinoma, 0.8% for adeno-squamous cell carcinoma, 3.0% for large cell carcinoma, 9.3% for small cell carcinoma, and 3.3% for others.[@bib10] The Tokushima Registry showed that the proportion was 51% for adenocarcinoma, 25% for squamous cell carcinoma, 3% for large cell carcinoma, 13% for small cell carcinoma, and 8% for others.[@bib11] Our registry showed a higher proportion of adenocarcinoma and a lower proportion of squamous cell carcinoma and small cell carcinoma compared with these two registries, when males and females were combined. Histological type is known to influence the choice of therapeutic strategy.[@bib10], [@bib11] Therefore, the frequency of histological types may be different among the participating hospitals, which may have resulted in the differences in the proportion of histological types among the registries.

These two relevant registries permitted calculation of the prevalence of each disease stage in patients grouped according to histological type, and reported that small cell carcinoma was more frequently diagnosed at an advanced stage compared with the other histological types of lung cancer.[@bib10], [@bib11] The JLC Registry reported that stage IV accounted for 40.3% of small cell carcinoma cases, while stage IV accounted for 18.6% of non-small cell carcinoma cases.[@bib10] The Tokushima Registry showed that stage IV accounted for 49.8% of small cell carcinoma cases, while stage IV accounted for 29.6% of non-small cell carcinoma cases.[@bib11] Although our registry generally showed a similar pattern, stage IV accounted for a smaller percentage of small cell carcinoma cases in our registry compared with these two registries possibly due to the issue mentioned earlier.

The Japanese Association of Clinical Cancer Centers reported a 5-year relative survival rate of 43.8% in 10512 lung cancer patients who were registered between 2004 and 2007 (stage I, 39.3%; stage II, 7.2%; stage III, 24.9%; stage IV, 27.1%; and others or unknown, 1.5%).[@bib20] Our lung cancer participants had a better 5-year relative survival rate than the lung cancer patients involved in the Japanese Association of Clinical Cancer Centers, because our population had a higher frequency of stage I patients.

The JLC Registry demonstrated that more advanced stage was associated with poorer prognosis in lung cancer patients after 5 years of follow-up.[@bib10] Furthermore, small cell carcinoma had the worst prognosis, followed by large cell carcinoma, squamous cell carcinoma/adeno-squamous cell carcinoma, and adenocarcinoma.[@bib10] Our results were consistent with the results of this registry. Although our participants had more favorable clinical characteristics than the participants of this registry, our survival analysis also identified similar predictive factors for all-cause mortality in lung cancer patients. In addition to cancer stage and histological type, we observed that ever smoker, low body mass index, and elevated serum CEA level were also crudely associated with poorer prognosis after adjustment for age and study entry year. Factors associated with poorer prognosis identified among the total cases of lung cancer were similar to those of adenocarcinoma.

The strength of the present study is the enrollment of male and female lung cancer patients from many participating hospitals nationwide. In addition, we provided sex-specific information on the characteristics of Japanese lung cancer patients. On the other hand, the present study has several limitations. First, the survival analysis was conducted among cases registered within 90 days after their diagnosis, not definite incident cases. There might have been a bias resulting from selecting survival patients in our prognostic assessment. Therefore, the true prognosis of lung cancer may be worse than we observed. Second, we identified factors predicting all-cause mortality in lung cancer patients after adjustment only for age and entry year. These predictive factors may be interrelated, while other factors such as performance status and treatment may confound the associations we observed. Therefore, caution should be taken in interpreting our results. Finally, there were missing data on some variables in the BBJ Project database. The main reason for missing data was that the data were collected mostly from medical records in which limited clinical information was available. Another possible reason for missing data on cancer stage was that the data were collected through medical records regarding each component of the TNM classification (included in the Japanese Classification of Lung Cancer, the 6th edition (2003)), but not stage. Furthermore, some cancer patients admitted participating hospitals for only therapeutic procedures or follow-up after being diagnosed at other hospitals. It is unclear whether these reasons for missing data had a crucial effect on our results.

In conclusion, the findings of lung cancer patient characteristics detailed in this report are to some extent in accordance with other nationwide or local registries on lung cancer, with the requirement of caution that our patients had less advanced stages of lung cancer, compared with other registries. In the survival analysis, we found that some characteristics at study entry would be crudely associated with all-cause mortality in Japanese lung cancer patients. In spite of the caution mentioned earlier, the BBJ Project can be expected to provide reliable and valuable evidence on lung cancer.
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###### 

Characteristics of the 2299 overall male lung cancer patients in the BioBank Japan Project. Data are also presented specifically for the 764 male lung cancer patients registered within 90 days after their diagnosis and those grouped according to age at study entry.

Table 1

                                      Overall participants   Those registered within 90 days after diagnosis                                   
  ----------------------------------- ---------------------- ------------------------------------------------- ----- ------ ----- ------ ----- ------
  **Body mass index**                                                                                                                          
   \<18.5 kg/m^2^                     243                    11.0                                              79    10.5   18    10.2   61    10.6
   18.5--24.9 kg/m^2^                 1605                   72.3                                              545   72.4   129   73.3   416   72.1
   ≥25.0 kg/m^2^                      371                    16.7                                              129   17.1   29    16.5   100   17.3
   Unknown                            80                                                                       11           2            9     
  **Smoking habit**                                                                                                                            
   Never                              267                    11.7                                              77    10.1   16    9.0    61    10.4
   Ever (current/former)              2017                   88.3                                              686   89.9   162   91.0   524   89.6
   Unknown                            15                                                                       1            0            1     
  **Alcohol drinking habit**                                                                                                                   
   Never                              603                    26.5                                              198   26.0   42    23.7   156   26.7
   Ever (current/former)              1669                   73.5                                              563   74.0   135   76.3   428   73.3
   Unknown                            27                                                                       3            1            2     
  **History of COPD**                                                                                                                          
   Absence                            2214                   96.3                                              731   95.7   173   97.2   558   95.2
   Presence                           85                     3.7                                               33    4.3    5     2.8    28    4.8
  **History of IP/PF**                                                                                                                         
   Absence                            2246                   97.7                                              745   97.5   175   98.3   570   97.3
   Presence                           53                     2.3                                               19    2.5    3     1.7    16    2.7
  **Family history of lung cancer**                                                                                                            
   Absence                            1990                   86.6                                              654   85.6   154   86.5   500   85.3
   Presence                           309                    13.4                                              110   14.4   24    13.5   86    14.7
  **Stage**                                                                                                                                    
   Occult                             10                     0.6                                               1     0.2    0     0.0    1     0.2
   0                                  8                      0.5                                               1     0.2    1     0.8    0     0.0
   IA                                 565                    34.4                                              178   33.2   44    33.1   134   33.3
   IB                                 349                    21.2                                              121   22.6   20    15.0   101   25.1
   IIA                                47                     2.9                                               17    3.2    5     3.8    12    3.0
   IIB                                143                    8.7                                               41    7.6    12    9.0    29    7.2
   IIIA                               202                    12.3                                              57    10.6   16    12.0   41    10.2
   IIIB                               172                    10.5                                              61    11.4   19    14.3   42    10.4
   IV                                 147                    8.9                                               59    11.0   16    12.0   43    10.7
   Unknown                            656                                                                      228          45           183   
  **Histological type**                                                                                                                        
   Adenocarcinoma                     1141                   55.5                                              388   56.3   99    60.4   289   55.0
   Squamous cell carcinoma            587                    28.6                                              185   26.9   38    23.2   147   28.0
   Large cell carcinoma               80                     3.9                                               31    4.5    12    7.3    19    3.6
   Small cell carcinoma               148                    7.2                                               53    7.7    10    6.1    43    8.2
   Others                             99                     4.8                                               32    4.6    5     3.0    27    5.1
   Unknown                            244                                                                      75           14           61    
  **Serum CEA level**                                                                                                                          
   \<5 ng/mL                          1547                   74.3                                              479   70.3   116   72.5   363   69.7
   ≥5 ng/mL                           535                    25.7                                              202   29.7   44    27.5   158   30.3
   Unknown                            217                                                                      83           18           65    

Abbreviations: CEA, carcinoembryonic antigen; COPD, chronic obstructive pulmonary disease; IP/PF, interstitial pneumonia/pulmonary fibrosis.

###### 

Characteristics of the 1283 overall female lung cancer patients in the BioBank Japan Project. Data are also presented specifically for the 415 female lung cancer patients registered within 90 days after their diagnosis and those grouped according to age at study entry.

Table 2

                                      Overall participants   Those registered within 90 days after diagnosis                                    
  ----------------------------------- ---------------------- ------------------------------------------------- ----- ------ ----- ------- ----- ------
  **Body mass index**                                                                                                                           
   \<18.5 kg/m^2^                     158                    12.7                                              52    12.8   16    12.9    36    12.8
   18.5--24.9 kg/m^2^                 900                    72.2                                              287   70.7   94    75.8    193   68.4
   ≥25.0 kg/m^2^                      189                    15.2                                              67    16.5   14    11.3    53    18.8
   Unknown                            36                                                                       9            0             9     
  **Smoking habit**                                                                                                                             
   Never                              942                    74.1                                              281   68.2   74    59.7    207   71.9
   Ever (current/former)              330                    25.9                                              131   31.8   50    40.3    81    28.1
   Unknown                            11                                                                       3            0             3     
  **Alcohol drinking habit**                                                                                                                    
   Never                              887                    70.0                                              281   68.5   62    50.0    219   76.6
   Ever (current/former)              381                    30.0                                              129   31.5   62    50.0    67    23.4
   Unknown                            15                                                                       5            0             5     
  **History of COPD**                                                                                                                           
   Absence                            1274                   99.3                                              413   99.5   124   100.0   289   99.3
   Presence                           9                      0.7                                               2     0.5    0     0.0     2     0.7
  **History of IP/PF**                                                                                                                          
   Absence                            1270                   99.0                                              411   99.0   123   99.2    288   99.0
   Presence                           13                     1.0                                               4     1.0    1     0.8     3     1.0
  **Family history of lung cancer**                                                                                                             
   Absence                            1093                   85.2                                              352   84.8   93    75.0    259   89.0
   Presence                           190                    14.8                                              63    15.2   31    25.0    32    11.0
  **Stage**                                                                                                                                     
   Occult                             5                      0.5                                               1     0.3    0     0.0     1     0.5
   0                                  1                      0.1                                               0     0.0    0     0.0     0     0.0
   IA                                 459                    48.5                                              139   43.2   41    41.0    98    44.1
   IB                                 178                    18.8                                              62    19.3   19    19.0    43    19.4
   IIA                                24                     2.5                                               9     2.8    4     4.0     5     2.3
   IB                                 52                     5.5                                               23    7.1    7     7.0     16    7.2
   IIIA                               80                     8.5                                               32    9.9    12    12.0    20    9.0
   IIIB                               67                     7.1                                               23    7.1    9     9.0     14    6.3
   IV                                 80                     8.5                                               33    10.2   8     8.0     25    11.3
   Unknown                            337                                                                      93           24            69    
  **Histological type**                                                                                                                         
   Adenocarcinoma                     1006                   85.9                                              322   82.4   98    82.4    224   82.4
   Squamous cell carcinoma            80                     6.8                                               32    8.2    9     7.6     23    8.5
   Large cell carcinoma               11                     0.9                                               6     1.5    2     1.7     4     1.5
   Small cell carcinoma               34                     2.9                                               16    4.1    4     3.4     12    4.4
   Others                             40                     3.4                                               15    3.8    6     5.0     9     3.3
   Unknown                            112                                                                      24           5             19    
  **Serum CEA level**                                                                                                                           
   \<5 ng/mL                          954                    79.2                                              286   73.3   91    79.1    195   70.9
   ≥5 ng/mL                           251                    20.8                                              104   26.7   24    20.9    80    29.1
   Unknown                            78                                                                       25           9             16    

Abbreviations: CEA, carcinoembryonic antigen; COPD, chronic obstructive pulmonary disease; IP/PF, interstitial pneumonia/pulmonary fibrosis.

###### 

Characteristics of the male lung cancer patients registered in the BioBank Japan Project within 90 days after their diagnosis, grouped according to histological type.

Table 3

                                      Histological type                                         
  ----------------------------------- ------------------- ------ ----- ------ ---- ------- ---- ------
  **Age at study entry**                                                                        
   20--29 yr                          0                   0.0    0     0.0    0    0.0     0    0.0
   30--39 yr                          5                   1.3    2     1.1    0    0.0     0    0.0
   40--49 yr                          20                  5.2    5     2.7    2    6.5     1    1.9
   50--59 yr                          74                  19.1   31    16.8   10   32.3    9    17.0
   60--69 yr                          157                 40.5   62    33.5   9    29.0    18   34.0
   70--79 yr                          114                 29.4   75    40.5   10   32.3    23   43.4
   80--89 yr                          18                  4.6    10    5.4    0    0.0     2    3.8
   ≥90 yr                             0                   0.0    0     0.0    0    0.0     0    0.0
  **Body mass index**                                                                           
   \<18.5 kg/m^2^                     31                  8.1    19    10.4   3    9.7     6    11.8
   18.5--24.9 kg/m^2^                 285                 74.6   130   71.0   25   80.6    35   68.6
   ≥25.0 kg/m^2^                      66                  17.3   34    18.6   3    9.7     10   19.6
   Unknown                            6                          2            0            2    
  **Smoking habit**                                                                             
   Never                              57                  14.7   12    6.5    0    0.0     1    1.9
   Ever (current/former)              331                 85.3   173   93.5   31   100.0   51   98.1
   Unknown                            0                          0            0            1    
  **Alcohol drinking habit**                                                                    
   Never                              88                  22.7   55    29.9   12   38.7    15   28.8
   Ever (current/former)              299                 77.3   129   70.1   19   61.3    37   71.2
   Unknown                            1                          1            0            1    
  **History of COPD**                                                                           
   Absence                            380                 97.9   172   93.0   28   90.3    49   92.5
   Presence                           8                   2.1    13    7.0    3    9.7     4    7.5
  **History of IP/PF**                                                                          
   Absence                            379                 97.7   181   97.8   30   96.8    50   94.3
   Presence                           9                   2.3    4     2.2    1    3.2     3    5.7
  **Family history of lung cancer**                                                             
   Absence                            332                 85.6   158   85.4   25   80.6    49   92.5
   Presence                           56                  14.4   27    14.6   6    19.4    4    7.5
  **Stage**                                                                                     
   Occult                             0                   0.0    1     0.7    0    0.0     0    0.0
   0                                  1                   0.3    0     0.0    0    0.0     0    0.0
   IA                                 132                 42.4   29    21.2   5    21.7    5    16.1
   IB                                 62                  19.9   40    29.2   9    39.1    3    9.7
   IIA                                12                  3.9    2     1.5    0    0       2    6.5
   IIB                                13                  4.2    21    15.3   3    13.0    0    0.0
   IIIA                               26                  8.4    23    16.8   0    0       6    19.4
   IIIB                               30                  9.6    14    10.2   3    13.0    7    22.6
   IV                                 35                  11.3   7     5.1    3    13.0    8    25.8
   Unknown                            77                         48           8            22   
  **Serum CEA level**                                                                           
   \<5 ng/mL                          252                 68.9   125   76.2   20   74.1    27   61.4
   ≥5 ng/mL                           114                 31.1   39    23.8   7    25.9    17   38.6
   Unknown                            22                         21           4            9    

Abbreviations: CEA, carcinoembryonic antigen; COPD, chronic obstructive pulmonary disease; IP/PF, interstitial pneumonia/pulmonary fibrosis.

###### 

Characteristics of the female lung cancer patients registered in the BioBank Japan Project within 90 days after their diagnosis, grouped according to histological type.

Table 4

                                      Histological type                                        
  ----------------------------------- ------------------- ------ ---- ------- --- ------- ---- -------
  **Age at study entry**                                                                       
   20--29 yr                          0                   0.0    0    0.0     0   0.0     0    0.0
   30--39 yr                          3                   0.9    1    3.1     0   0.0     0    0.0
   40--49 yr                          12                  3.7    0    0.0     1   16.7    1    6.3
   50--59 yr                          83                  25.8   8    25.0    1   16.7    3    18.8
   60--69 yr                          119                 37.0   11   34.4    3   50.0    3    18.8
   70--79 yr                          95                  29.5   9    28.1    1   16.7    9    56.3
   80--89 yr                          10                  3.1    3    9.4     0   0.0     0    0.0
   ≥90 yr                             0                   0.0    0    0.0     0   0.0     0    0.0
  **Body mass index**                                                                          
   \<18.5 kg/m^2^                     37                  11.7   4    12.5    2   33.3    3    20.0
   18.5--24.9 kg/m^2^                 227                 71.8   19   59.4    4   66.7    11   73.3
   ≥25.0 kg/m^2^                      52                  16.5   9    28.1    0   0.0     1    6.7
   Unknown                            6                          0            0           1    
  **Smoking habit**                                                                            
   Never                              240                 75.0   6    18.8    1   16.7    7    46.7
   Ever (current/former)              80                  25.0   26   81.3    5   83.3    8    53.3
   Unknown                            2                          0            0           1    
  **Alcohol drinking habit**                                                                   
   Never                              227                 71.4   18   56.3    2   33.3    8    53.3
   Ever (current/former)              91                  28.6   14   43.8    4   66.7    7    46.7
   Unknown                            4                          0            0           1    
  **History of COPD**                                                                          
   Absence                            321                 99.7   32   100.0   6   100.0   16   100.0
   Presence                           1                   0.3    0    0.0     0   0.0     0    0.0
  **History of IP/PF**                                                                         
   Absence                            319                 99.1   32   100.0   6   100.0   16   100.0
   Presence                           3                   0.9    0    0.0     0   0.0     0    0.0
  **Family history of lung cancer**                                                            
   Absence                            273                 84.8   28   87.5    3   50.0    14   87.5
   Presence                           49                  15.2   4    12.5    3   50.0    2    12.5
  **Stage**                                                                                    
   Occult                             1                   0.4    0    0.0     0   0.0     0    0.0
   0                                  0                   0.0    0    0.0     0   0.0     0    0.0
   IA                                 134                 48.7   1    5.9     0   0.0     2    16.7
   IB                                 52                  18.9   3    17.6    3   50.0    2    16.7
   IIA                                8                   2.9    0    0.0     1   16.7    0    0.0
   IIB                                13                  4.7    4    23.5    2   33.3    2    16.7
   IIIA                               27                  9.8    2    11.8    0   0.0     1    8.3
   IIIB                               15                  5.5    4    23.5    0   0.0     3    25.0
   IV                                 25                  9.1    3    17.6    0   0.0     2    16.7
   Unknown                            47                         15           0           4    
  **Serum CEA level**                                                                          
   \<5 ng/mL                          239                 77.6   19   67.9    4   66.7    7    43.8
   ≥5 ng/mL                           69                  22.4   9    32.1    2   33.3    9    56.3
   Unknown                            14                         4            0           0    

Abbreviations: CEA, carcinoembryonic antigen; COPD, chronic obstructive pulmonary disease; IP/PF, interstitial pneumonia/pulmonary fibrosis.

###### 

Age-adjusted hazard ratios for all-cause mortality in male and female-combined lung cancer patients registered in the BioBank Japan Project within 90 days after their diagnosis, grouped according to patient characteristics, after a mean follow-up of 5.2 years. Data are also presented specifically for male and female-combined lung cancer patients with adenocarcinoma.

                                   Those registered within 90 days after diagnosis   Those with adenocarcinoma                                                              
  -------------------------------- ------------------------------------------------- --------------------------- ------ ------- ---------------- ----- ----- ------ ------- ----------------
  **Age at study entry**                                                                                                                                                    
   Additional 1 yr increase                                                                                             1.03    (1.02--1.04)                        1.03    (1.02--1.05)
  **Body mass index**                                                                                                                                                       
   \<18.5 kg/m^2^                  128                                               75                          592    1.09    (0.83--1.43)     66    34    365    1.21    (0.79--1.83)
   18.5--24.9 kg/m^2^              791                                               404                         4132   1.00    Reference        484   206   2912   1.00    Reference
   ≥25.0 kg/m^2^                   185                                               80                          1039   0.78    (0.60--1.02)     111   40    680    0.84    (0.57--1.25)
   Additional 1 kg/m^2^ increase                                                                                        0.97    (0.94--0.99)                        0.95    (0.91--0.99)
  **Smoking habit**                                                                                                                                                         
   Never                           336                                               129                         2056   1.00    Reference        277   94    1804   1.00    Reference
   Ever (current/former)           781                                               442                         3748   1.42    (1.07--1.88)     392   193   2183   1.72    (1.17--2.54)
  **Alcohol drinking habit**                                                                                                                                                
   Never                           460                                               227                         2401   1.00    Reference        300   124   1772   1.00    Reference
   Ever (current/former)           654                                               342                         3392   0.86    (0.70--1.07)     367   162   2204   0.85    (0.61--1.19)
  **Stage**                                                                                                                                                                 
   I                               468                                               122                         3365   1.00    Reference        355   74    2655   1.00    Reference
   II                              86                                                44                          509    2.57    (1.63--4.06)     44    25    259    3.24    (1.64--6.40)
   III                             172                                               125                         643    5.63    (4.05--7.82)     97    65    418    6.59    (4.05--10.73)
   IV                              87                                                80                          173    14.83   (10.15--21.66)   57    54    122    21.20   (12.37--36.33)
  **Histological type**                                                                                                                                                     
   Adenocarcinoma                  671                                               288                         3994   1.00    Reference                                   
   Squamous cell carcinoma         208                                               123                         950    1.27    (1.00--1.62)                                
   Large cell carcinoma            35                                                17                          190    0.96    (0.50--1.84)                                
   Small cell carcinoma            66                                                50                          201    2.03    (1.44--2.85)                                
  **Serum CEA level**                                                                                                                                                       
   \<5 ng/mL                       739                                               283                         4535   1.00    Reference        474   151   3179   1.00    Reference
   ≥5 ng/mL                        294                                               215                         1095   2.55    (2.07--3.13)     173   118   758    2.75    (2.05--3.69)

Abbreviations: CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio; PYFU, person-years of follow-up. The hazard ratios were calculated using a Cox proportional hazards regression model stratified by sex and institution and adjusted for age at study entry and entry year.
